Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) EBITDA (2020 - 2025)

Historic EBITDA for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to -$41.0 million.

  • Maravai Lifesciences Holdings' EBITDA rose 7522.49% to -$41.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$194.2 million, marking a year-over-year increase of 531.15%. This contributed to the annual value of -$235.6 million for FY2024, which is 64449.25% down from last year.
  • Latest data reveals that Maravai Lifesciences Holdings reported EBITDA of -$41.0 million as of Q3 2025, which was up 7522.49% from -$66.3 million recorded in Q2 2025.
  • In the past 5 years, Maravai Lifesciences Holdings' EBITDA ranged from a high of $180.7 million in Q2 2022 and a low of -$165.6 million during Q3 2024
  • Its 5-year average for EBITDA is $37.1 million, with a median of -$7.2 million in 2023.
  • In the last 5 years, Maravai Lifesciences Holdings' EBITDA surged by 179082.51% in 2021 and then plummeted by 97422.97% in 2024.
  • Quarter analysis of 5 years shows Maravai Lifesciences Holdings' EBITDA stood at $154.5 million in 2021, then dropped by 29.31% to $109.2 million in 2022, then plummeted by 106.54% to -$7.2 million in 2023, then tumbled by 427.3% to -$37.7 million in 2024, then decreased by 8.83% to -$41.0 million in 2025.
  • Its EBITDA was -$41.0 million in Q3 2025, compared to -$66.3 million in Q2 2025 and -$49.2 million in Q1 2025.